Tepmetko
(Tepotinib)ApprovedSmall molecule
EMD SeronoTepotinib is used to treat a specific type of lung cancer (non-small cell lung cancer) in patients whose cancer cells have a particular genetic mutation called METex14 skipping.[2] Tepmetko is currently approved and in use across 8 indications[4].[1]
Tepmetko is one of 271 small molecule programs targeting Colorectal Neoplasm. It is currently in Approved.
8
Indications
24
Total Trials
9
Active Trials
270
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tepmetko
EMD SeronoApproved
Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Show 1 more trial
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Phase 2·NCT03940703·140 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 2·NCT03940703·140 enrolledInteraction2 trials
Hepatocellular Carcinoma2 trials
Immunotherapy1 trial
12 more indications
Metastatic Colorectal Cancer1 trial
Solid Tumors1 trial
Tepotinib in Solid Tumors Harboring MET Alterations
Unknown status·—·Phase 2·NCT04647838·100 enrolled
Phase II1 trial
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Phase 2·NCT02864992·337 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 2·NCT02864992·337 enrolledLocally Advanced or Metastatic NSCLC1 trial
Treatment1 trial
Brain Tumors1 trial
Regulatory
FDA Approval Timeline[5]
Feb 3, 2021
TEPMETKO
NDA NDA214096
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tepmetko drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tepotinib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]